PRaG regimens for rechallenge in a patient with acquired resistance to PD-1 inhibitor in advanced refractory renal pelvis carcinoma: A case report
Advances in Radiotherapy & Nuclear Medicine · 2023
DOI: 10.36922/arnm.0441 ↗Kurz gefasst
Fallbericht in der Zeitschrift Advances in Radiotherapy & Nuclear Medicine, 2023. Verfasst von Zhihui Hong und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Despite the burgeoning popularity of programmed death-1 (PD-1) inhibitors in cancer treatment, it is not uncommon for patients who initially respond to this therapy to experience relapse over time. Here, we present the case of a patient with advanced renal pelvis carcinoma who had received prior treatment with chemotherapy and PD-1 inhibitor therapy but ultimately experienced disease progression. Subsequently, the patient underwent a combination therapy known as PRaG 2.0, which included PD-1 inhibitor, radiotherapy, granulocyte-macrophage colony-stimulating factor, and interleukin-2, resulting in effective disease control without significant adverse events. The duration of disease control lasted for a period of 10 months.
Zitieren
APA
Hong, Z., Xu, H., Kong, Y., Xu, M., Ma, Y., Xing, P., & Zhang, L. (2023). PRaG regimens for rechallenge in a patient with acquired resistance to PD-1 inhibitor in advanced refractory renal pelvis carcinoma: A case report. Advances in Radiotherapy & Nuclear Medicine. https://doi.org/10.36922/arnm.0441
Vancouver
Hong Z, Xu H, Kong Y, Xu M, Ma Y, Xing P, et al. PRaG regimens for rechallenge in a patient with acquired resistance to PD-1 inhibitor in advanced refractory renal pelvis carcinoma: A case report. Advances in Radiotherapy & Nuclear Medicine. 2023. doi:10.36922/arnm.0441
BibTeX
@article{Hong2023,
author = {Hong, Zhihui and Xu, Hong and Kong, Yuehong and Xu, Meiling and Ma, Yifu and Xing, Pengfei and Zhang, Liyuan},
title = {PRaG regimens for rechallenge in a patient with acquired resistance to PD-1 inhibitor in advanced refractory renal pelvis carcinoma: A case report},
journal = {Advances in Radiotherapy & Nuclear Medicine},
year = {2023},
doi = {10.36922/arnm.0441}
}
EUVIMED